Sierra Oncology

194 articles with Sierra Oncology

• Sierra Oncology to Present at the Cowen 40th Annual Health Care Conference

  2/25/2020

  Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled "Building MOMENTUM for Patients with Myelofibrosis" at the Cowen 40th Annual Health Care Conference

• Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead

  2/6/2020

  Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that the Series A convertible voting preferred stock issued in its recently completed $103.0 million financing (gross proceeds) have been fully converted into shares of common stock.

• Sierra Oncology Announces Reverse Stock Split

  1/22/2020

  Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its board of directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-40.

• Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

  12/7/2019

  New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology Annual Meeting

• Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH

  12/2/2019

  Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8th

• 

  Clinical Catch-Up: November 18-22

  11/25/2019

  As usual, it was a busy week for clinical trial updates. Here’s a look.

• Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis

  11/20/2019

  Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it has launched the MOMENTUM clinical trial for patients with myelofibrosis

• Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference

  11/14/2019

  Sierra Oncology, Inc. announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled "Building Momentum for Patients with Myelofibrosis" at the Jefferies 2019 London Healthcare Conference in London, United Kingdom.

• Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants

  11/7/2019

  The offering is expected to close on November 13, 2019, subject to customary closing conditions.

• Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib

  11/7/2019

  Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra

• Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019

  11/6/2019

  New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients are nearly 10-times more likely to remain transfusion free compared to ruxolitinib treated patients

• Sierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and Warrants

  11/6/2019

  Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it intends to offer and sell shares of Series A convertible preferred stock, together with Series A warrants and Series B warrants, each to purchase shares of common stock, in an underwritten public offering.

• Sierra Oncology Reports Third Quarter 2019 Results

  11/4/2019

  MOMENTUM Phase 3 myelofibrosis clinical trial anticipated to launch in Q4 2019

• Sareum notes Sierra Oncology has reported its Second Quarter 2019 Results and Published its Form 10-Q with the US SEC

  8/8/2019

  Sareum Holdings PLC, the specialist small molecule drug development business notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, has announced its financial and operational results for the second quarter 2019 ended 30 June 2019.

• Sierra Oncology Reports Second Quarter 2019 Results

  8/8/2019

  Sierra Oncology, Inc. reported its financial and operational results for the second quarter ended June 30, 2019.

• Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York - Aug. 7, 2019

  8/7/2019

  Presentation scheduled for 2:30 pm ET on August 14, 2019

• Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets

  6/27/2019

  Sierra Oncology, Inc. announced plans to prioritize its existing resources on the development of momelotinib, its differentiated Phase 3 drug candidate for the treatment of patients with myelofibrosis.

• Sierra Announces Momelotinib Granted FDA Fast Track Designation

  6/5/2019

  Sierra Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib, a JAK1, JAK2 and ACVR1 inhibitor, for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.

• Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial

  6/4/2019

  Sierra Oncology, Inc. announced that it has obtained regulatory clarity with the U.S. Food and Drug Administration (FDA) concerning the design of a Phase 3 clinical trial for momelotinib intended to support potential registration of this differentiated drug candidate for the treatment of previously JAK inhibitor treated myelofibrosis patients.

• Sierra Holds Analyst & Investor Event for SRA737 - June 3, 2019

  6/3/2019

  Sierra Oncology, Inc. is holding an analyst and investor event featuring distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit, to discuss clinical findings and possible next steps for its oral, highly selective Chk1 inhibitor, SRA737.